Tonix Pharmaceuticals (TNXP) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

TNXP Tonix Pharmaceuticals

Watchlist

0.1883
-0.0005-0.26%

Close Nov 27 16:00 ET

0.1893
+0.0010+0.53%

Pre 08:33 ET

35.19MMarket Cap-2P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Tonix Pharma Talks NDA for Fibromyalgia Drug, FDA Decision on NDA Acceptance Expected December 2024 | NASDAQ:TNXP
Proactive InvestorsNov 27 10:54 ET
WHO Extends Mpox Emergency; Canada Reports First Clade I Case
Seeking AlphaNov 23 14:48 ET
Express News | World Health Organization Says Mpox Continues To Constitute A Public Health Emergency Of International Concern
BenzingaNov 22 12:43 ET
Looking Into Tonix Pharmaceuticals's Recent Short Interest
BenzingaNov 22 12:00 ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
BenzingaNov 20 16:10 ET
Quantum-Si QSI SkyWater Deal Expansion; Tonix Pharmaceuticals TNXP Phase 3 Data
BioPharmCatalystNov 20 08:21 ET

Comments

Angelos

Yesterday 01:01

$Tonix Pharmaceuticals (TNXP.US)$
#TNXP - Expected earnings Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp. (TNXP) is expected to report $-2.03 for Q3 2024

Angelos

Yesterday 00:57

$Tonix Pharmaceuticals (TNXP.US)$
#TNXP - Expected earnings Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp. (TNXP) is expected to report $-2.03 for Q3 2024

Goldman Sachs

Yesterday 00:23

$Tonix Pharmaceuticals (TNXP.US)$
#TNXP - Expected earnings Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp. (TNXP) is expected to report $-2.03 for Q3 2024

Goldman Sachs

Yesterday 00:15

$Tonix Pharmaceuticals (TNXP.US)$ https://youtu.be/v_VIj3lMETU?si=mKwShpRtJb54IFS2

我要向钱看

Yesterday 00:05

CONTINUE FROM PREVIOUS UPDATE

$Tonix Pharmaceuticals (TNXP.US)$ Dr. Seth Lederman, CEO of Tonix Pharmaceuticals (NASDAQ:TNXP), joined Steve Darling from Proactive to unveil promising results at the ACR Convergence 2024 Annual Meeting from the company’s Phase 3 RESILIENT trial of its proprietary sublingual bedtime medication for fibromyalgia. The trial met its primary endpoint, achieving a statistically significant reduction in daily pain compared to a placebo.
Additionally, the treatment demonstr...